TRI

TRIVARX FPO [TRI]
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Hawthorn East, Australia.
Healthcare · ASX Small Cap
$0.0150 +0.0%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when TRI triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track TRI — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Bollinger squeeze with volume pouring in — this is the kind of setup that often precedes a big move
  • Volume surging at 2.0x normal while price falls — heavy selling pressure
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Adequate cash runway (6 quarters)
  • 4C filed 2026-07-28
  • Very high P/S ratio (1188.1x)
  • Micro-cap ($5-20M) - high risk
  • Sentiment is mixed — no strong consensus either way
  • Penny stock risk ($0.015)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 33% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-0.88%/day)
Ask Scout AI about TRI
"What's driving TRI today?" "How does TRI compare to peers?" "Key risks for TRI?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Appendix 4E - Preliminary Final Report
LOW June 2026 Quarterly Activities Report and Appendix 4C
MEDIUM Stabl-Im clinical trial supply milestone achieved

Recent ASX Announcements

2026-08-27 Appendix 4E - Preliminary Final Report PRICE SENSITIVE
2026-07-28 June 2026 Quarterly Activities Report and Appendix 4C PRICE SENSITIVE
2026-07-15 Stabl-Im clinical trial supply milestone achieved PRICE SENSITIVE

Key Metrics

$17.3M
Market Cap
502K
Avg Volume
2.0x
Vol Ratio
$0.01 — $0.04
52-Week Range
N/A
Short Interest
6 qtrs
Cash Runway
-61.2%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 78%
LLeader vs LaggardlaggardRS: -17
IInstitutional SponsorshipweakInst: 7%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:TRI vs REGTRI vs CANTRI vs BIT
Scout Pro — Deeper Analysis for TRI
Try Pro free for 30 days
Share this analysis

Track TRI and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required